cangrelor

Also known as AR-C69931MX, ARL69931, Kengreal®, [dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid

Cangrelor, sold under the brand name Kengreal among others, is a P2Y12 inhibitor FDA approved as of June 2015 as an antiplatelet drug for intravenous application. Some P2Y12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation.

In the Vinony graph

Within Vinony's link graph, cangrelor is referenced by 300 other articles, and connects out to adenosine receptor, intravenous infusion and defusion and hirudin.

Vinony files it under Adenosine diphosphate receptor inhibitors, Chemicals using indexlabels and Drugs with non-standard legal status.

Its subject is documented across 13 Wikipedia language editions.

Key facts

Drug.image: Cangrelor structure.svg
Drug.image_class: skin-invert-image
Drug.width: 300
Drug.tradename: Kengreal, Kengrexal, others
Drug.DailyMedID: Cangrelor
Drug.routes_of_administration: Intravenous
Drug.ATC_prefix: B01
Drug.ATC_suffix: AC25
Drug.legal_CA: Rx-only
Drug.legal_US: Rx-only
Drug.legal_EU: Rx-only
Drug.bioavailability: 100% (IV)
Drug.protein_bound: ~97–98%.
Drug.metabolism: Rapid deactivation in the circulation (independent of CYP system)
Drug.elimination_half life: ~3–6 minutes
Drug.excretion: Kidney (58%), Bile duct (35%)
Drug.index2_label: as salt
Drug.IUPHAR_ligand: 1776

via Wikipedia infobox

Chemical data

Formula: C17H25Cl2F3N5O12P3S2
Molecular weight: 776.4 g/mol
IUPAC name: [dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid
SMILES: CSCCNC1=C2C(=NC(=N1)SCCC(F)(F)F)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O
InChIKey: PAEBIVWUMLRPSK-IDTAVKCVSA-N
XLogP: -1
Polar surface area: 307 Å²
H-bond donors: 7
H-bond acceptors: 21
Formal charge: 0

via PubChem

Drug data · ChEMBL

Max clinical phase: Approved
Molecule type: Small molecule
First approval: 2015
Admin. routes: parenteral
Indications: Recurrent thrombophlebitis, acute coronary syndrome, ST Elevation Myocardial Infarction, ischemia

via ChEMBL · EBI

Research

852 papers

Cangrelor in clinical use.Future cardiology · 2020
Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives.Journal of the American Heart Association · 2021
Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.JAMA · 2012
Cangrelor for the treatment of patients with Arterial Thrombosis.Expert opinion on pharmacotherapy · 2018
The role of cangrelor in acute and high-risk PCI settings.European heart journal. Cardiovascular pharmacotherapy · 2025

via PubMed

Wikidata facts

Subclass of: chemical compound
Mass: 774.948313
Has use: medication

Show 7 more facts

chemical formula: C₁₇H₂₅Cl₂F₃N₅O₁₂P₃S₂
isomeric SMILES: CSCCNC1=NC(=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O)SCCC(F)(F)F
canonical SMILES: CSCCNC1=NC(=NC2=C1N=CN2C3C(C(C(O3)COP(=O)(O)OP(=O)(C(P(=O)(O)O)(Cl)Cl)O)O)O)SCCC(F)(F)F
World Health Organisation international non-proprietary name: cangrelor
defined daily dose: 50
significant drug interaction: apixaban
Commons category: Cangrelor